Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

Publisher： Karger

E-ISSN： 1662-6575|4|3|470-474

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.4, Iss.3, 2011-09, pp. : 470-474

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 23-31

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

By  

Oncology Research and Treatment, Vol. 36, Iss. 3, 2013-02 ,pp. : 95-100

Karger

Access to resources Recommend Favorite

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : E1-E6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diabetes-Induced Renal Vascular Dysfunction Is Normalized by Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase

By  

Journal of Vascular Research, Vol. 42, Iss. 4, 2005-07 ,pp. : 284-291

Karger

Access to resources Recommend Favorite